Thierry Schaeverbeke

<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

Pierre‐Antoine Juge, Joyce Lee, Esther Ebstein et al. · New England Journal of Medicine · 2018 · 502 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

Jacques‐Eric Gottenberg, Philippe Ravaud, Thomas Bardin et al. · Arthritis & Rheumatism · 2010 · 303 citations

Life Sciences, Immunology, Pharmacotherapy +17

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study

Marie Kostine, L. Rouxel, Thomas Barnetche et al. · Annals of the Rheumatic Diseases · 2017 · 302 citations

Life Sciences, Immunology, Oncology +17

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Cem Gabay, Bruno Fautrel, Jürgen Rech et al. · Annals of the Rheumatic Diseases · 2018 · 291 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Marie Kostine, Axel Finckh, Clifton O. Bingham et al. · Annals of the Rheumatic Diseases · 2020 · 276 citations · Full text

Medicine, Immunology, Oncology +17